Valneva (VLS)

12.170
+0.130(+1.08%)
  • Volume:
    211,748
  • Bid/Ask:
    0.000/0.000
  • Day's Range:
    12.000 - 12.270
  • Type:Equity
  • Market:France
  • ISIN:FR0004056851

VLS Overview

Prev. Close
12.04
Day's Range
12-12.27
Revenue
144.47M
Open
12.15
52 wk Range
4.385-15.6
EPS
-1
Volume
211,748
Market Cap
1.12B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
703,619
P/E Ratio
-
Beta
0.41
1-Year Change
143.72%
Shares Outstanding
91,637,954
Next Earnings Date
Aug 10, 2021
What is your sentiment on Valneva?
or
Vote to see community's results!

Valneva News

Valneva Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesBuyBuyStrong BuyStrong BuyStrong Buy
Technical IndicatorsStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy
SummaryStrong BuyStrong BuyStrong BuyStrong BuyStrong Buy

Valneva Company Profile

Valneva Company Profile

Employees
532
Market
France

Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.

Read More
  • Sales !!
    0
    • 20 eur today?
      2
      • no 50eur a least
        0
    • buy now?
      0
      • volume inquiétant today non ?
        0
        • It's simply not true, Sylvain Lorient (Aug 01)! Valneva on Aug 22 released the initial results from their first PhII study on Lyme Disease (https://valneva.com/press-release/valneva-announces-positive-initial-results-for-phase-2-study-of-lyme-disease-vaccine-candidate/). Over the "next few months further PhII data will be released".. and only after that AND discussing PhIII protocol with FDA can final tests be started.
          1
          • Valneva has started the final tests ( on humans ) for lyme disease vaccine.
            0
            • France Valneva get contract whit UK for distribution vactine covid-19
              0
              Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
              Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.